This will help advance the field of organoid-based cancer models." The review on tissue dissociation techniques is poised to make a significant impact on oncology research, especially for solid ...

Professor Meghan Morrissey earns an innovation award to program immune cells to attack cancer tumors. #immunotherapy ...

Learn about our Editorial Policies. Chimeric antigen receptor (CAR) T cell therapy leverages patients’ immune systems to fight cancer. This immunotherapy greatly expanded treatment options for cancers ...

a non-cellular structural component of the tumor extracellular matrix, is being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. Pyxis Oncology’s therapeutic ...

are rare mesenchymal tumors and were among the first solid tumor types for which such a novel treatment (in this case imatinib) became available. The tyrosine kinase inhibitor imatinib targets the ...

The FDA approval extends to various cancer types, though it is not approved for combination with Yervoy, limiting its use in some contexts. Dr. Balazs Halmos discusses the significance of the approval ...

PYX-201, an antibody-drug conjugate (ADC) that uniquely targets EDB+FN, a non-cellular structural component of the tumor extracellular matrix, is being evaluated in ongoing Phase 1 clinical studies in ...

a non-cellular structural component of the tumor extracellular matrix, is being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. Pyxis Oncology’s therapeutic ...

Pancreatic cancer has the worst survival rates among all solid tumor types, and its incidence is increasing. Hypoxic conditions that arise from an imbalance between increased oxygen consumption and an ...

Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® ...